90Y and 177LU labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy

被引:61
作者
Liu, S [1 ]
Cheung, E [1 ]
Ziegler, MC [1 ]
Rajopadhye, M [1 ]
Edwards, DS [1 ]
机构
[1] Dupont Merck Pharmaceut Co, Med Imaging Div, N Billerica, MA 01862 USA
关键词
D O I
10.1021/bc000146n
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The Y-90 and Lu-177 complexes (RP697 and RP688, respectively) of a DOTA-conjugated vitronectin receptor antagonist (SU015: 2-(1,4,7, 10-tetraaza-4,7, 10-tris(carboxymethyl)-1-cyclododecyl)acetyl-Glu-(cyclo{ Lys-Arg-Gly-Asp-D-Phe})(cyclo{Lys-Arg-Gly-Asp-D-Phe})were prepared by reacting SU015 with the radiometal chloride in ammonium acetate buffer (pH > 7.2) in the presence of an antioxidant (sodium gentisate, GA). Through a series of radiolabeling experiments, it was found that there are many factors influencing the rate of Y-90 chelation and the radiolabeling efficiency of SU015. These include the purity of SU015, the pH, reaction temperature, and heating time, as well as the presence of trace metal contaminants, such as Ca2+, Fe3+, and Zn2+. The chelation of Y-90 by SU015 is slow, so that heating at elevated temperatures (50-100 degreesC) is needed to complete the Y-90-labeling. The rate of Y-90 chelation is also dependent on the pH of the reaction mixture. Under optimized radiolabeling conditions (pH 7.2-7.8 and heating at 50-100 degreesC for 5-10 min), the minimum amount of SU015 required to achieve 95% RCP for RP697 is similar to 25 mug for 20 mCi of (YCl3)-Y-90 corresponding to a SU015:Y-90 ratio of similar to 30:1.
引用
收藏
页码:559 / 568
页数:10
相关论文
共 61 条
  • [1] ARG-GLY-ASP CONSTRAINED WITHIN CYCLIC PENTAPEPTIDES - STRONG AND SELECTIVE INHIBITORS OF CELL-ADHESION TO VITRONECTIN AND LAMININ FRAGMENT-P1
    AUMAILLEY, M
    GURRATH, M
    MULLER, G
    CALVETE, J
    TIMPL, R
    KESSLER, H
    [J]. FEBS LETTERS, 1991, 291 (01) : 50 - 54
  • [2] Biological evaluation of thrombus imaging agents utilizing water soluble phosphines and tricine as coligands when used to label a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with Tc-99m
    Barrett, JA
    Crocker, AC
    Damphousse, DJ
    Heminway, SJ
    Liu, S
    Edwards, DS
    Lazewatsky, JL
    Kagan, M
    Mazaika, TJ
    Carroll, TR
    [J]. BIOCONJUGATE CHEMISTRY, 1997, 8 (02) : 155 - 160
  • [3] Biological evaluation of Tc-99m-labeled cyclic glycoprotein IIb/IIIa receptor antagonists in the canine arteriovenous shunt and deep vein thrombosis models: Effects of chelators on biological properties of [Tc-99m]chelator-peptide conjugates
    Barrett, JA
    Damphousse, DJ
    Heminway, SJ
    Liu, S
    Edwards, DS
    Looby, RJ
    Carroll, TR
    [J]. BIOCONJUGATE CHEMISTRY, 1996, 7 (02) : 203 - 208
  • [4] BLOOD CH, 1995, BIOCHIM BIOPHYS ACTA, V1032, P410
  • [5] INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS
    BROOKS, PC
    MONTGOMERY, AMP
    ROSENFELD, M
    REISFELD, RA
    HU, TH
    KLIER, G
    CHERESH, DA
    [J]. CELL, 1994, 79 (07) : 1157 - 1164
  • [6] Tumor angiogenesis - new drugs on the block
    Brower, V
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (10) : 963 - 968
  • [7] Cheesman E. H., 1999, Journal of Labelled Compounds and Radiopharmaceuticals, V42, pS164
  • [8] THE NEGOTIATED SYLLABUS - WHAT IS IT AND HOW IS IT LIKELY TO WORK
    CLARKE, DF
    [J]. APPLIED LINGUISTICS, 1991, 12 (01) : 13 - 28
  • [9] STABILITIES OF THE ALKALINE-EARTH AND DIVALENT TRANSITION-METAL COMPLEXES OF THE TETRAAZAMACROCYCLIC TETRAACETIC ACID LIGANDS
    CLARKE, ET
    MARTELL, AE
    [J]. INORGANICA CHIMICA ACTA, 1991, 190 (01) : 27 - 36
  • [10] METAL-COMPLEXES OF CYCLIC TETRA-AZATETRA-ACETIC ACIDS
    DELGADO, R
    DASILVA, JJRF
    [J]. TALANTA, 1982, 29 (10) : 815 - 822